- $2.58bn
- $2.63bn
- $9.68m
Brief: Precigen Announces Full FDA Approval Of Papzimeos
US FDA approves Precigen's immunotherapy for rare respiratory disease
U.S. RESEARCH ROUNDUP-Applied Materials, Precigen, Transdigm Group
Precigen Inc expected to post a loss of 8 cents a share - Earnings Preview
Precigen Inc reports results for the quarter ended March 31 - Earnings Summary
Precigen Inc expected to post a loss of 8 cents a share - Earnings Preview
Precigen Inc reports results for the quarter ended December 31 - Earnings Summary
Precigen Inc expected to post a loss of 6 cents a share - Earnings Preview
Precigen Inc expected to post a loss of 6 cents a share - Earnings Preview
Brief: Precigen On Dec 18, Entered Into Asset Acquisition Agreement With Innovator 21, LLC
Precigen Inc reports results for the quarter ended September 30 - Earnings Summary
Precigen Inc expected to post a loss of 8 cents a share - Earnings Preview
Brief: Precigen Says On Oct 4, A&R License Agreement Was Terminated
Precigen Inc reports results for the quarter ended in June - Earnings Summary
Precigen Inc expected to post a loss of 10 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Duolingo, Beyond Meat, Oil stocks
U.S. STOCKS ON THE MOVE-Parker Hannifin, Corpay, Sezzle
U.S. STOCKS ON THE MOVE-Datadog, Palantir, NRG Energy
Gene therapy firm Precigen drops on $30 mln stock offering